These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 25234165)

  • 1. MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.
    Jagannathan S; Vad N; Vallabhapurapu S; Vallabhapurapu S; Anderson KC; Driscoll JJ
    Leukemia; 2015 Mar; 29(3):727-38. PubMed ID: 25234165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1.
    Amodio N; Di Martino MT; Foresta U; Leone E; Lionetti M; Leotta M; Gullà AM; Pitari MR; Conforti F; Rossi M; Agosti V; Fulciniti M; Misso G; Morabito F; Ferrarini M; Neri A; Caraglia M; Munshi NC; Anderson KC; Tagliaferri P; Tassone P
    Cell Death Dis; 2012 Nov; 3(11):e436. PubMed ID: 23190608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma.
    Yang Y; Chen Y; Saha MN; Chen J; Evans K; Qiu L; Reece D; Chen GA; Chang H
    Leukemia; 2015 Mar; 29(3):715-26. PubMed ID: 25179733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lnc NEAT1/miR-29b-3p/Sp1 form a positive feedback loop and modulate bortezomib resistance in human multiple myeloma cells.
    Che F; Ye X; Wang Y; Ma S; Wang X
    Eur J Pharmacol; 2021 Jan; 891():173752. PubMed ID: 33253679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5.
    Zhu YX; Tiedemann R; Shi CX; Yin H; Schmidt JE; Bruins LA; Keats JJ; Braggio E; Sereduk C; Mousses S; Stewart AK
    Blood; 2011 Apr; 117(14):3847-57. PubMed ID: 21289309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
    Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The novel orally active proteasome inhibitor K-7174 exerts anti-myeloma activity in vitro and in vivo by down-regulating the expression of class I histone deacetylases.
    Kikuchi J; Yamada S; Koyama D; Wada T; Nobuyoshi M; Izumi T; Akutsu M; Kano Y; Furukawa Y
    J Biol Chem; 2013 Aug; 288(35):25593-25602. PubMed ID: 23878197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.
    Kuhn DJ; Chen Q; Voorhees PM; Strader JS; Shenk KD; Sun CM; Demo SD; Bennett MK; van Leeuwen FW; Chanan-Khan AA; Orlowski RZ
    Blood; 2007 Nov; 110(9):3281-90. PubMed ID: 17591945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
    Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
    Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma.
    Hideshima T; Bradner JE; Wong J; Chauhan D; Richardson P; Schreiber SL; Anderson KC
    Proc Natl Acad Sci U S A; 2005 Jun; 102(24):8567-72. PubMed ID: 15937109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib reduces the tumorigenicity of multiple myeloma via downregulation of upregulated targets in clonogenic side population cells.
    Nara M; Teshima K; Watanabe A; Ito M; Iwamoto K; Kitabayashi A; Kume M; Hatano Y; Takahashi N; Iida S; Sawada K; Tagawa H
    PLoS One; 2013; 8(3):e56954. PubMed ID: 23469177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance.
    Tian Z; D'Arcy P; Wang X; Ray A; Tai YT; Hu Y; Carrasco RD; Richardson P; Linder S; Chauhan D; Anderson KC
    Blood; 2014 Jan; 123(5):706-16. PubMed ID: 24319254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.
    Niewerth D; Kaspers GJ; Assaraf YG; van Meerloo J; Kirk CJ; Anderl J; Blank JL; van de Ven PM; Zweegman S; Jansen G; Cloos J
    J Hematol Oncol; 2014 Jan; 7():7. PubMed ID: 24418325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy.
    Balsas P; Galán-Malo P; Marzo I; Naval J
    Leuk Res; 2012 Feb; 36(2):212-8. PubMed ID: 21978467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo.
    Bono C; Karlin L; Harel S; Mouly E; Labaume S; Galicier L; Apcher S; Sauvageon H; Fermand JP; Bories JC; Arnulf B
    Haematologica; 2012 Jul; 97(7):1101-9. PubMed ID: 22271897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.
    Gomez-Bougie P; Wuillème-Toumi S; Ménoret E; Trichet V; Robillard N; Philippe M; Bataille R; Amiot M
    Cancer Res; 2007 Jun; 67(11):5418-24. PubMed ID: 17545623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model.
    Stessman HA; Baughn LB; Sarver A; Xia T; Deshpande R; Mansoor A; Walsh SA; Sunderland JJ; Dolloff NG; Linden MA; Zhan F; Janz S; Myers CL; Van Ness BG
    Mol Cancer Ther; 2013 Jun; 12(6):1140-50. PubMed ID: 23536725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines.
    de Carvalho F; Costa ET; Camargo AA; Gregorio JC; Masotti C; Andrade VC; Strauss BE; Caballero OL; Atanackovic D; Colleoni GW
    PLoS One; 2011; 6(11):e27707. PubMed ID: 22110734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LncRNA H19 overexpression induces bortezomib resistance in multiple myeloma by targeting MCL-1 via miR-29b-3p.
    Pan Y; Zhang Y; Liu W; Huang Y; Shen X; Jing R; Pu J; Wang X; Ju S; Cong H; Chen H
    Cell Death Dis; 2019 Feb; 10(2):106. PubMed ID: 30728351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes.
    David E; Kaufman JL; Flowers CR; Schafer-Hales K; Torre C; Chen J; Marcus AI; Sun SY; Boise LH; Lonial S
    Blood; 2010 Dec; 116(24):5285-8. PubMed ID: 20844234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.